60
Registered trials
15
Recruiting
42
Completed trials
28
Sponsors
22
Countries
Phase III:
14
Phase II/III:
1
Phase II:
27
Phase I/II:
12
Phase III/IV:
1
Phase IV:
1
Phase I (Other):
2
Phase I (FiH):
1
Other:
1
Oversight events:
2 serious breaches
4 temporary halts
2 urgent safety measures
2 unexpected events
across 8 trials
View oversight register →
Indications tested
Hepatocellular carcinoma
7
Colorectal cancer
4
Renal cell carcinoma
4
Endometrial cancer
3
Ovarian cancer
2
Small cell lung cancer extensive stage
2
Triple negative breast cancer
2
Non-small cell lung cancer
2
Ewing's sarcoma recurrent
1
Extra-osseous Ewing´s sarcoma metastatic
1
Hepatic cancer
1
Laryngeal squamous cell carcinoma
1
Sponsors using this IMP
Merck Sharp & Dohme LLC
26
AstraZeneca AB
3
Eisai Limited
3
Assistance Publique Hopitaux De Paris
2
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
2
Institut Gustave Roussy
2
AbbVie Deutschland GmbH & Co. KG
1
AGO Research GmbH
1
Bluepharma Industria Farmaceutica S.A.
1
Bristol-Myers Squibb Services Unlimited Company
1
CatalYm GmbH
1
Centre Hospitalier Universitaire De Bordeaux
1
All trials
60 total-
DRUP trial Recruiting
Showing 1–24 of 60 trials